Bettendorf M, Heinrich U E, Schönberg D K, Grulich-Henn J
Kinderklinik, Pädiatrische Endokrinologie, Universität Heidelberg, Germany.
Eur J Pediatr. 1997 Dec;156(12):911-5. doi: 10.1007/s004310050741.
Height predictions based on three different methods (Bayley-Pinneau [BP], Tanner-Whitehouse Mark II [TW II], Roche-Wainer-Thissen [RWT]) were compared to adult heights in 19 males with constitutional tall stature previously treated with high-dose testosterone oenanthate for 6 months (group A) and 25 untreated tall males (group B). Their chronological ages (CA) at the initial evaluation of tall stature ranged from 12.1 to 16.6 years in group A and from 10.4 to 15.7 years in group B; at the time of assessment of adult height ages ranged from 18.0 to 26.5 years and from 18.4 to 25.1 years, respectively. Height measurements and predicted adult heights were expressed as height standard deviation scores (height SDS) for chronological age using the tables of Reinken and van Oost [14]. Height SDS in group A were 2.8 (range = 1.8-5.4) before testosterone treatment, 3.0 (range = 2.0-4.8) thereafter and finally 3.0 (range = 2.1-4.2) (P = NS) and in group B 2.7 (range = 0.5-4.3) and 2.4 (range = 1.3-3.5) (P = NS). A significant difference between adult height SDS and predicted height SDS according to BP was detected both in group A (3.0; range = 2.1-4.2 vs 3.6; range = 2.4-5.0. P < or = 0.004) and group B (2.4; range = 1.3-3.5 vs 3.0; range = 2.0-4.9; P < or = 0.0002), whereas no significant difference between adult height SDS and predicted height SDS according to TW II and RWT was found in either group. These data indicate that BP height predictions overestimated adult height in our patient group of treated and untreated males with constitutional tall stature. In contrast, the TW II and RWT methods were more accurate in predicting adult height in these patients, but also failed to demonstrate that testosterone therapy in boys with constitutional tall stature can be limited to a 6-month period in order to reduce adult height.
The widely used height prediction method of BP is inaccurate in boys with constitutional tall stature. High dose testosterone treatment fails to reduce adult height in these individuals when discontinued before complete closure of the epiphyses.
将基于三种不同方法(贝利 - 平诺[BP]、坦纳 - 怀特豪斯第二版[TW II]、罗氏 - 韦纳 - 蒂森[RWT])预测的身高与19名曾接受大剂量庚酸睾酮治疗6个月的体质性高身材男性(A组)和25名未接受治疗的高身材男性(B组)的成人身高进行比较。他们在初次评估高身材时的实足年龄(CA)在A组为12.1至16.6岁,在B组为10.4至15.7岁;在评估成人身高时,年龄分别为18.0至26.5岁和18.4至25.1岁。身高测量值和预测的成人身高使用赖肯和范奥斯特[14]的表格表示为按实足年龄的身高标准差分数(身高SDS)。A组在睾酮治疗前身高SDS为2.8(范围 = 1.8 - 5.4),治疗后为3.0(范围 = 2.0 - 4.8),最后为3.0(范围 = 2.1 - 4.2)(P = 无显著差异),B组为2.7(范围 = 0.5 - 4.3)和2.4(范围 = 1.3 - 3.5)(P = 无显著差异)。在A组(3.0;范围 = 2.1 - 4.2对比3.6;范围 = 2.4 - 5.0。P≤0.004)和B组(2.4;范围 = 1.3 - 3.5对比3.0;范围 = 2.0 - 4.9;P≤0.0002)中均检测到根据BP预测的成人身高SDS与实际成人身高SDS之间存在显著差异,而在两组中均未发现根据TW II和RWT预测的成人身高SDS与实际成人身高SDS之间存在显著差异。这些数据表明,在我们治疗和未治疗的体质性高身材男性患者组中,BP身高预测高估了成人身高。相比之下,TW II和RWT方法在预测这些患者的成人身高方面更准确,但也未能证明对于体质性高身材男孩的睾酮治疗可以限制在6个月以降低成人身高。
广泛使用的BP身高预测方法在体质性高身材男孩中不准确。在骨骺完全闭合前停药时,高剂量睾酮治疗未能降低这些个体的成人身高。